Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart

J Clin Oncol. 2019 Apr 1;37(10):765-769. doi: 10.1200/JCO.18.01927. Epub 2019 Feb 22.

Authors

Neha Vapiwala¹, Michael S Hofman^{2

3}, Declan G Murphy^{2

3}, Scott Williams^{2

3}, Christopher Sweeney⁴

Affiliations

¹ 1 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
² 2 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ 3 University of Melbourne, Parkville, VIC, Australia.
⁴ 4 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

PMID: 30794477
DOI: 10.1200/JCO.18.01927

No abstract available

MeSH terms

Antigens, Surface / analysis
Diagnostic Imaging / methods*
Diagnostic Imaging / standards
Glutamate Carboxypeptidase II / analysis
Humans
Magnetic Resonance Imaging / methods*
Magnetic Resonance Imaging / standards
Male
Positron Emission Tomography Computed Tomography / methods*
Positron Emission Tomography Computed Tomography / standards
Prostate-Specific Antigen / analysis
Prostatectomy / methods
Prostatic Neoplasms / diagnosis
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / surgery
Reproducibility of Results
Sensitivity and Specificity

Substances

Antigens, Surface
FOLH1 protein, human
Glutamate Carboxypeptidase II
Prostate-Specific Antigen